To exclude REL amplification as a potential compounding factor, we performed the same analyses in patients without REL amplification or polysomies, and found that only the correlation between TP53 mutations (but not p63+) and upregulated REL mRNA (but not the c-Rel protein) in ABC-DLBCL was affected. The gene discussed is TP53; the disease is diffuse large B-cell lymphoma.